Intercytex was originally founded in 2000 and listed on the Alternative Investment Market in February 2006. As a result of the recession and disappointing trial results with another product, Intercytex Group plc delisted from AIM last year and was forced to sell all of its assets. Intercytex Ltd and VAVELTA® were purchased by a private concern, Regenerative Solutions Ltd, which is now the holding company. Today Intercytex is funded in part by a series of grants from the North West Development Agency, the UK Government’s Technology Strategy Board, the European Union and by an agreement with the US Department of Defence as well as private investment.  Intercytex Ltd is focused on developing and marketing VAVELTA® to ensure its potential and benefits can be realised.

The reformed company is headed up by Dr Paul Kemp, who is one of the pioneers in Regenerative Medicine and has over 20 years commercial experience in the field both in the U.S. and U.K. The company is based in the Core Technology Facility in Manchester and is currently involved in two clinical trials in the UK and US.